FDA Approves Hameln’s Radiation Exposure Therapies
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency encouraged NDA filings for Ca-DTPA and Zn-DTPA in a September 2003 guidance. The drugs are used to treat internal contamination with plutonium, americium or curium.